Plaque stabilisation by systemic and local drug administration

Heart

Volumn 90, Issue 12, 2004, Pages 1392-1394

  Spratt, J C ^a   Camenzind, Edoardo ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; CALCIUM ANTAGONIST; CLOPIDOGREL; CORTICOSTEROID; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; GADOLINIUM; HEPARIN; IMMUNOMODULATING AGENT; IOHEXOL; IRON OXIDE; LOW MOLECULAR WEIGHT HEPARIN; NICOTINIC ACID; RAPAMYCIN; RECEPTOR BLOCKING AGENT; SIMVASTATIN; STATINE DERIVATIVE; TICLOPIDINE; UNCLASSIFIED DRUG;

ATHEROSCLEROTIC PLAQUE; BLEEDING; CATHETER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG ELUTING STENT; EARLY DIAGNOSIS; HEART DISEASE; HUMAN; INTRAVASCULAR ULTRASOUND; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR; THERMOGRAPHY;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; CORONARY ARTERIOSCLEROSIS; FIBRINOLYTIC AGENTS; HEART CATHETERIZATION; HUMANS; RISK FACTORS; STENTS;

EID: 10344229928     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.034975     Document Type: Conference Paper

References (30)

1. Virmani R, Kolodgie FD, Burke AP, et al. Lesson from sudden cardiac death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-75.
2. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
3. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cordial 1988;12:56-62.
4. Riofoul G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002;106:804-8.
5. Badimon JJ, Fuster V. Can we image the "active" thrombus? Arterioscler Thromb Vasc Biol 2002;22:1753-4.
6. Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque. Circulation 2003;107:2072-5.
7. de Korte CL, Schaar JA, Mastik F, et al. Intravascular elastography: from bench to bedside. J Interv Cardiol 2003;16:253-9.
8. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35:1-10.
9. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheromas: a potential mechanism of lesion stabilization. Circulation 1998;97:2433-44.
10. Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001;104:387-92.
11. Schartz GG, Olsson AG, Ezekowski MD, et al. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial, JAMA 2001;285:1711-8.
12. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination far the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
13. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin far unstable coronary artery disease. N Engl J Med 1997;337:447-52.
14. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med 1983;309:396-403.
15. Yusef S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation. N Eng J Med 2001;345:494-502.
16. Yusuf S, Mehla SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-72.
17. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999;100:2045-8.
18. Monroe SV, Kerensky RA, Rivera E, et al. Pharmacological plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes. J Am Coll Cardiol 2003;41:23S-30S.
19. Yusef S, Sleight P, Pogue J. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Eng J Med 2000;342:145-53.
20. Claridge MW, Mobbs SD, Quick CR, et al. ACE inhibitors increase type III collagen synthesis: a potential explanation for reduction in acute vascular events by ACE inhibitors. Eur J Vasc Endovasc Surg 2004;28:67-70.
21. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000;102:1503-10.
22. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon diet heart study. Circulation 1999;99:779-85.
23. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive therapy far the prevention of restenosis after coronary artery stent implantation (IMPRESS study). J Am Coll Cardiol 2002;40:1935-42.
24. Brara PS, Moussavian M, Grise MA, et al. Pilot trial of oral rapamycin for recalcitrant restenosis. Circulation 2003;107:1722-4.
25. Camenzind E, Bakker WH, Reijs A, et al. Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. Circulation 1997;96:154-66.
26. Esente P, Kaplan AV, Ford JK, et al. Local intramural delivery of heparin during primary angioplasty for acute myocardial infarction: results of the local PAMI pilot study. Cath Cardiovasc Interv 1999;47:237-42.
27. Stefan KR, Pawel B, Jack ML, et al. Local delivery of enoxaporin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American local Lovenox NIR assessment study (The POLONIA Study). Circulation 2001;103:26-31.
28. Serruys PW, van Hout B, Bannier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998;352:673-81.
29. Liu X, Huang Y, Hanet C, et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 2003;60:172-8.
30. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.